
Galleon Pharmaceuticals lands $10M for sleep apnea, COPD drug
Galleon Pharmaceuticals Inc. in suburban Philadelphia has raised $10 million to help discover medicines to treat breathing control conditions, like sleep apnea and COPD.
Galleon Pharmaceuticals Inc. in suburban Philadelphia has raised $10 million to help discover medicines to treat breathing control conditions, like sleep apnea and COPD.
ImThera Medical Inc. put to bed more than $1 million of a possible $2.2 million funding round that will go toward completing clinical trials of an implantable neurostimulation device for sleep apnea. Officials at the San Diego, California-based company described the financing as a “tranche in a larger $5 million B round,” which is expected […]
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
Bob Schmidt thinks he has an answer for the mega trends of rising healthcare costs, fewer doctors to treat more patients, and provider pay-cuts by the federal government: eHealth. And for Schmidt's Cleveland Medical Devices (CleveMed), eHealth means dreaming up diagnostic devices for sleep and movement disorders that can cut up to 90 percent of the cost of traditional tests -- and even help primary care physicians find new revenue sources.
Zeo Inc. raised $1 million of a proposed $1.5 million debt financing round. The company, formerly known as Axon Labs, opened the round July 30, with three investors participating, according to a Securities & Exchange Commission filing. The filing lists board members Ronald Chwang of iD Ventures America, Peter Meekin of Trident Capital and iRobot […]
NxThera Inc. has raised $1 million from the sale of equity and debt, according to documents filed with the Securities and Exchange Commission. The start-up, based in St. Paul, is developing ways to treat enlarged prostates by using vapor injections and thermal energy to kill tissue. CEO Robert Paulson formerly led Restore Medical Inc., a […]
Cleveland Medical Devices Inc. has been awarded $60,000 from the Cuyahoga County New Product Development and Entrepreneurship Loan Fund to step up commercialization of its SleepView device for sleep apnea screening at home. CleveMed has a lineup of wireless diagnostic sleep systems, including SleepView, which is the smallest and lightest home sleep monitor with an […]
Starting next year, the newest doctors-in-training who take care of you in some hospitals might be a little more rested. The Accreditation Council for Graduate Medical Education recently proposed new standards for the nation’s residency training programs. The biggest change calls for limiting shifts for first-year residents to a maximum of 16 hours. For more […]
Apnex Medical Inc., a St. Paul-based startup developing technology to treat obstructive sleep apnea (OSA), has named Charles McKhann as its new CEO. McKhann, who previously served as a global vice president of marketing for Boston Scientific Corp.’s (NYSE: BSX) cardiac rhythm management division, replaces founder and executive director Robert Atkinson. While at Johnson & […]
Senate Democrats have reached a "broad plan" to settle their differences over the proposed government-run insurance plan, and things aren't looking good for strong supporters of the so-called public option.
The company is developing an implantable neurostimulation device that activates muscles in a patient's upper airway to prevent the tongue from blocking the airway during sleep.
Internal medicine residents at Cleveland's University Hospitals and the local VA Medical Center are required to take a three to four hour nap during their 30-hour shifts. Summa Health System in Akron has for years experimented by limiting internal medicine residents to 16-hour shifts -- and most pull just 12 hours. It's part of an evolution -- or revolution, depending on who you talk to -- on how to manage the work hours of medicine's youngest doctors.
Inspire Medical Systems Inc. in Minneapolis has raised $17 million in a second round of venture capital to pay for ongoing clinical trials of its device to treat one type of sleep apnea.